中文名稱

SLIGKV-NH2（1毫克）

英文名字

SLIGKV-NH2

供應商

Alomone

產品貨號

ALO-GPS-100-1

產品報價

￥已停產

產品說明書

點擊查看

購買方式

銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868

產品新聞

背景資料

Protease-activated receptors (PARs) 1-4 belong to the superfamily of G-protein-coupled receptors (GPCRs) that are self-activated by a tethered sequence exposed by proteolysis of an extracellular domain. PARs are activated by proteolysis in response to endogenous and exogenous proteases and can contribute to both cellular homeostasis and pathology. In the case of PAR2, the exposed human peptide SLIGVK-NH2 remains tethered on the receptor and activates a primary binding site located on second loop of the receptor. As an obvious consequence of its activation mechanism, PAR2 is associated with pathologies with a strong protease release. The involvement of PAR2 in inflammatory diseases such as arthritis, lung inflammation (asthma), inflammatory bowel disease, sepsis, and pain disorders makes PAR2 an attractive target for drug intervention. The extracellular N-terminus of PAR2 (46 residues long) contains a putative trypsin cleavage site R34 and S35, followed by LIGKV. The human-derived SLIGKV-NH2 is a small peptide that mimics the ligand binding properties of the tethered ligand exposed by proteolysis of the N-terminus from the natural receptor and hence, a significant tool used to study PAR2.

產品描述

A Potent Agonist of PAR2, Derived from PAR2 Auto-Ligand Sequence

產品形式

Protease-activated receptors (PARs) 1-4 belong to the superfamily of G-protein-coupled receptors (GPCRs) that are self-activated by a tethered sequence exposed by proteolysis of an extracellular domain. PARs are activated by proteolysis in response to endogenous and exogenous proteases and can contribute to both cellular homeostasis and pathology. In the case of PAR2, the exposed human peptide SLIGVK-NH2 remains tethered on the receptor and activates a primary binding site located on second loop of the receptor. As an obvious consequence of its activation mechanism, PAR2 is associated with pathologies with a strong protease release. The involvement of PAR2 in inflammatory diseases such as arthritis, lung inflammation (asthma), inflammatory bowel disease, sepsis, and pain disorders makes PAR2 an attractive target for drug intervention. The extracellular N-terminus of PAR2 (46 residues long) contains a putative trypsin cleavage site R34 and S35, followed by LIGKV. The human-derived SLIGKV-NH2 is a small peptide that mimics the ligand binding properties of the tethered ligand exposed by proteolysis of the N-terminus from the natural receptor and hence, a significant tool used to study PAR2.

保存建議

艾美捷為您提供的Alonmone Labs原裝進口的SLIGKV-NH2 (1 mg)產品可室溫運輸，建議您在收到產品后將其置于合適的溫度下保存。

其他

Alomone成立于1989年,已經成為全世界科學家信賴的最全面的離子通道研究工具供應商。產品覆蓋離子通道、G蛋白耦聯受體和神經信號研究所需的一抗、小分子、蛋白質和多肽等。所有Alomone產品均進行了生物實驗驗證，以凍干粉形式提供，可確保產品生物活性和保質期。Alomone可提供多種包裝規格，靈活方便。作為Alomone Labs在中國的區域總代理，艾美捷科技有限公司將為中國客戶提供最全面的Alomone Labs產品以及客戶訂制化服務。

注意

該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。

分享到：